skip to content

Roche Pharma R&D (pRED)

Our scientists are amongst the best in the industry, discovering and translating cutting-edge science in the pursuit of delivering life-changing benefits to patients.

We continue to be driven by our long-term aim to deliver these medical advances that provide greater benefits to patients, and at the same time, reduce the healthcare burden on society.

pRED's research spans across 7 disease areas:

andandand

pRED scientists pursue excellence. Patients are waiting, so by pushing boundaries pRED scientists make breakthroughs every day. Find out some examples of areas where pRED is leading the field.

Roche pRED publications

Roche is an innovation company pioneering the future of healthcare, science and R&D.

scientists are active members of the scientific community and publish in numerous peer-reviewed journals in the areas of Clinical Development, Pharmaceutical Sciences, Therapeutic Modalities and Translational Bioengineering; and

andandand

[Potrait]

Revolutionary discoveries in science are truly enabled when we have open minds and ears to share and collaborate.

Hans Clevers

Head of pRED, Roche

Meet the pRED scientists

At pRED, it’s not the easy questions that excite us, it’s the biggest challenges in healthcare. That’s why we’ve set ourselves big goals to discover treatments that provide greater benefits for patients at a lower cost to society. This means having the expertise, resources and latest technologies at our fingertips, within an organisation that nurtures innovation built on curiosity and responsibility.

Innovation

Roche R&D locations

We have research and development sites all around the world.

Modern architecture with sleek glass building on the left, reflecting light, against a clear blue sky and white geometric structure on the right. Minimalist and serene.
Decorative Illustration

Institute of Human Biology

The Institute of Human Biology (IHB) is dedicated to research on human biology and human model systems such as organoids. Roche Pharmaceutical Research and Early Development (pRED) established the IHB to take maximum advantage of the scientific and research expertise in both academia and the pharmaceutical industry, it will bring them closer together using human model systems to better predict a drug’s validity, and so translate pioneering science into breakthroughs for patients.

Innovation

Roche Accelerator

As Roche’s first in-house accelerator globally, Roche Accelerator aims to serve as an external innovation hub, to catalyze next-generation R&D and contribute to the innovation ecosystem.

[Thumbnail] RocheAccelerator
A diverse team of professionals at a creative agency collaborating in a bright, modern office space.

RNA Hub

An integrated multidisciplinary RNA research community with focus on oligonucleotides And access to all of Roche’s research capabilities

Joint postdoctoral programme with ETH Zurich

To advance the development and application of bioengineering in translational medicine, the ETH Zurich Department of Biosystems Science and Engineering and Roche Pharma Research and Early Development launched the Bio-​Engineering Systems for Therapeutics (BEST) postdoc programme in Basel.

Students in a lab wear white coats and safety goggles. One uses a pipette with a focused expression. The bright room has a collaborative atmosphere.